Hood River Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Hood River Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-53,483	Closed	-$8.28M	–	156
2021 Q2	$8.28M	Sell	53,483 -3,097	-5%	-$449K	0.25%	88
2021 Q1	$8.93M	Sell	56,580 -5,537	-9%	-$1.17M	0.29%	94
2020 Q4	$14.4M	Buy	62,117 +1,066	+2%	+$247K	0.48%	81
2020 Q3	$13.4M	Sell	61,051 -6,107	-9%	-$1.49M	0.58%	68
2020 Q2	$19.1M	Buy	67,158 +7,939	+13%	+$2.35M	0.86%	47
2020 Q1	$17.1M	Buy	59,219 +11,459	+24%	+$3.16M	0.98%	41
2019 Q4	$13.7M	Buy	47,760 +4,357	+10%	+$945K	0.59%	72
2019 Q3	$6.26M	Buy	+43,403	New	+$5.88M	0.32%	85

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hood River Capital Management's KPTI Position: Q3 2021 in Review

Hood River Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 53,483 shares — an estimated $8.28M sold.

Hood River Capital Management first reported a position in KPTI in Q3 2019 and held it in 8 quarters. The position peaked at $19.1M in Q2 2020. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

Hood River Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
Hood River Capital Management sold 53,483 Karyopharm Therapeutics shares in Q3 2021, an estimated $8.28M.
Hood River Capital Management first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 8 quarters.
Hood River Capital Management's Karyopharm Therapeutics position peaked at $19.1M in Q2 2020.
134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Hood River Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.